WideEyed,
What you're suggesting is certainly one possibility. I'm not certain that NWBO won't look to keep everything for themselves with a Hub and Spoke model where Advent, which they'll own is the hub, and hospitals and research institutions everywhere are the spokes.
Advent will operate corporate owned EDEN units, while each spoke will lease the units. All units will be monitored for performance by FlaskWorks, who'll also be responsible for the manufacturing and maintenance of the units, they'll also track every disposable cassette and be certain it's been properly disposed of after use.
As long as the hub and spoke model is acceptable internationally, Advent can set up other substantially sized hubs in other continents in the world, but I believe the spokes could be doing the bulk of the work.
The beauty of the spokes is that there is no cost to NWBO, in fact they would pay NWBO in a manner agreed to when they become a spoke. The hospital or research institution would already have cleanroom and cryogenic capabilities and a staff that's already well trained in using them. With perhaps a little additional training, and space for something the size of a computer printer, they can be all set up for making DCVax-L for their facility, and perhaps for others in their area.
No one has an accurate number for the cost of each EDEN unit or disposable cassette, but knowledgeable posters seem to believe it's under $100K. The very first batch of DCVax-L should make more money than the cost of the EDEN Unit making it.
A spoke activity might not pay anything until it's shipped an EDEN Unit to make its first batch of DCVax-L, it could pay out of the funds it collects for making the vaccine, and of course NWBO is paid according to some mutually agreed upon schedule for each batch of vaccine that's made or dosed.
I don't know that this will happen, but it is a way a tiny company could do it by themselves.
Gary
Bullish
AI
Market Data 
Markets 
